Atlassian (NASDAQ:TEAM) looks to continue its streak of outperforming consensus estimates in fiscal 2025 when it reports its second quarter financial results next week. "New price hikes announced ...
Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in early-stage MSA completed in November ...